Nivolumab
Opdivo (nivolumab) is an antibody pharmaceutical. Nivolumab was first approved as Opdivo on 2014-12-22. It is used to treat kidney neoplasms, lymphoma, melanoma, non-small-cell lung carcinoma, and squamous cell carcinoma amongst others in the USA. It has been approved in Europe to treat colorectal neoplasms, hodgkin disease, melanoma, mesothelioma, and non-small-cell lung carcinoma amongst others. The pharmaceutical is active against programmed cell death protein 1.
| Trade Name | Opdivo |
|---|---|
| Common Name | Nivolumab |
| ChEMBL ID | CHEMBL2108738 |
| Indication | colorectal neoplasms, hodgkin disease, kidney neoplasms, lymphoma, melanoma, mesothelioma, non-small-cell lung carcinoma, renal cell carcinoma, squamous cell carcinoma, squamous cell carcinoma of head and neck, transitional cell carcinoma, urinary bladder neoplasms, urologic neoplasms |
| Drug Class | Monoclonal antibodies: fully human, immunomodulating |
